Key result
Beta-blocker therapy appears to improve both quality of life and survival in patients with chronic heart failure by antagonizing sympathetic nervous system activation.
Why the study?
Does beta-blocker therapy improve quality of life and survival in patients with chronic heart failure due to systolic dysfunction?
Does beta-blocker therapy improve quality of life and survival in patients with chronic heart failure due to systolic dysfunction?
This review highlights the pathophysiological rationale and preliminary clinical evidence supporting the use of beta-blockers to improve survival and quality of life in chronic heart failure.
No takes yet. Share an insight, caveat, or question.
May support beta-blocker use in systolic HF; leaves open confirmation in large RCTs.
Jonathan Sackner‐Bernstein (1995) conducted a review in Chronic heart failure. Beta-blockers vs. Placebo was evaluated. Beta-blocker therapy appears to improve both quality of life and survival in patients with chronic heart failure by antagonizing sympathetic nervous system activation.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: